For fax submission, please ensure that your corrections are clearly legible. Use a fine ...... tered intravitreal ranibizumab on a pro-re-nata basis. 304. Overall, in ...
!"#$%&'()*$ !"#"$%#"$&'"$(#))*+$)*$,)-#$%#&./0"1 !!
2)-$/%3$+-45.&$,)-#$/)##"/&.)3+$*+,-+".%6.%$"/0#-,$)#$4,$1#21
!!
7)#$ *+,-+"$ +-45.++.)3$ (0"%+"$ .3+"#&$ ,)-#$ /)##"/&.)3+$ .3$ &'"$ )30.3"$ /)##"/&.)3$ *)#51 809%,+$.3:./%&"$&'"$0.3"$3-54"#$&)$9'./'$&'"$/)##"/&.)3$#"*"#+1
!!
2)-$/%3$%0+)$.3+"#&$,)-#$/)##"/&.)3+$.3$&'"$(#))*$;-#"+=$&%40"+$%3:$&'".#$0">"3:+$%#"$.3/0-:":1 80+)$ /'"/@$ &'"$ %//-#%/,$ )*$ +("/.%0$ /'%#%/&"#+=$ "D-%&.)3+=$ %3:$ "0"/&#)3./$ +-((0"5"3&%#, 5%&"#.%0$.*$%((0./%40"1$F*$3"/"++%#,$#"*"#$&)$&'"$!"#$%"&'()*+,-#.$1
!!
G'"$ (-40./%&.)3$ )*$ .3%//-#%&"$ :%&%$ +-/'$ %+$ :)+%>"+$ %3:$ -3.&+$ /%3$ '%6"$ +"#.)-+ /)3+"D-"3/"+1$;0"%+"$&%@"$(%#&./-0%#$/%#"$&'%&$%00$+-/'$:"&%.0+$%#"$/)##"/&1
!!
;0"%+"$ 9*% +*($ 5%@"$ /'%3>"+$ &'%&$ .36)06"$ )30,$ 5%&&"#+$ )*$ +&,0"1$ H"$ '%6"$ >"3"#%00, .3&#):-/":$*)#5+$&'%&$*)00)9$&'"$I)-#3%0J+$+&,0"1
!!
K-4+&%3&.%0$/'%3>"+$.3$/)3&"3&=$"1>1=$3"9$#"+-0&+=$/)##"/&":$6%0-"+=$&.&0"$%3:$%-&')#+'.($%#" 3)&$%00)9":$9.&')-&$&'"$%((#)6%0$)*$&'"$#"+()3+.40"$":.&)#1$F3$+-/'$%$/%+"=$(0"%+"$/)3&%/& &'"$L:.&)#.%0$M**./"$%3:$#"&-#3$'.+E'"#$/)3+"3&$&)>"&'"#$9.&'$&'"$(#))*1
!!
F*$9"$:)$3)&$#"/".6"$,)-#$/)##"/&.)3+$:-()-+%;20 minutes) at both the 3-month and 12-month follow-up visits, and compared with baseline measurements. Also, as a quantitative parameter of CNV response to treatment, the retinal thickness of the 1-mm central retina (central macular thickness), was measured at both the 3-month and 12-month follow-up visits, and compared with baseline measurements. Evidence of CNV growth was defined as an increase of at least 250 μm in GLD in late-phase ICGA frames at the 12-month follow-up visit compared with baseline. CNV
regression was defined as a decrease of at least 250 μm in GLD in late-phase ICGA frames at the 12-month follow-up visit compared with baseline. CNV stabilization was defined as an increase or decrease of less than 250 μm in GLD in late-phase ICGA frames at the 12-month follow-up visit compared with baseline. Presence of any intra/subretinal fluid on OCT scans was recorded at the 12-month follow-up visit, and correlated to ICGA evidence of CNV growth at the same time point. Statistical calculations were performed using Statistical Package for Social Sciences (version 17.0, SPSS Inc., Chicago, IL, USA). Paired t-test was used to evaluate changes of mean BCVA, mean lesion area, mean GLD and mean CMT at month 3 and at month 12 when compared to baseline. ANCOVA test was used to analyze variance on time among the covariates number of injections, age and entity of initial value. Spearman correlation coefficient
N
C
O
R
R
EC
TE
D
PR
O
O
F
intravitreal ranibizumab injections. Optical coherence tomography scans showing progressive reduction of intra/subretinal fluid and central macular thickness (CMT) from baseline (a, CMT=337 μm) to the 3-month (b, CMT=303 μm) and 12-month (c, CMT=264 μm) follow-up visits
U
165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181
Fig. 1 Late indocyanine green angiography frames showing an overall stabilization, from baseline (a) to the 3-month (b) and 12month (c) follow-up visits, of both the entire lesion area (from 5.08 mm2 to 4.99±3.5 mm2, and to 5.0 mm2, respectively), and greatest linear dimension (from 2.82 mm to 2.75 mm, and to 2.75 mm, respectively) of the occult choroidal neovascularization after repeated
Fig. 2 Late indocyanine green angiography frames showing an enlargement, from baseline (a) to the 3-month (b) and 12-month (c) follow-up visits, of both the entire lesion area (from 3.37 mm2 to 3.63 mm2, and to 4.18 mm2, respectively), and greatest linear dimension (from 2.54 mm to 2.69 mm, and to 2.92 mm, respectively)
of the occult choroidal neovascularization after repeated intravitreal ranibizumab injections. Optical coherence tomography scans showing progressive reduction and even disappearance of intra/subretinal fluid from baseline (a, CMT=285 μm) to the 3-month (b, CMT=281 μm) and 12-month (c, CMT=269 μm) follow-up visits
182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198
AUTHOR'S PROOF!
JrnlID 417_ArtID 1831_Proof# 1 - 29/09/2011
Graefes Arch Clin Exp Ophthalmol
208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233
Fifty-one treatment-naive eyes of 44 consecutive patients (ten males, 34 females, mean age 77.8±7.3 years) with occult CNV due to exudative AMD met the inclusion criteria, and were included in the analysis. All eyes with occult CNV had an associated serous or typical fibrovascular PED on OCT. Clinical data are summarized in Table 1. Patients received a mean of 5.5±2.7 (range 3–10) intravitreal ranibizumab injections during 12 months. No injectionrelated complications such as cataract, retinal detachment, or endophthalmitis were observed during the study period. When compared to baseline, BCVA significantly improved at the 3-month follow-up visit (60.5 ±22.0 vs 50.9 ±20.7 letters respectively; p=0.04), and stabilized at the 12-month followup visit (55.7 ±18.2 letters; p=0.05). CMT significantly improved at the 3-month follow-up visit (212.7 ±49.8 μm vs 281.0 ±61.3 μm at baseline; p
